Beyond the Traditional Commercial Model: Insights from Asembia 2026

Recorded from the floor of Asembia 2026, this episode explores how biopharma leaders are rethinking reimbursement, patient access and commercial strategy in an increasingly complex market. Host Kim Plesnarski is joined by Brian Siemak, VP of Portfolio Strategy at MannKind, and Terry Milton, AVP Field Reimbursement at Eli Lilly, to continue their on-stage panel discussion on the mounting pressure across gross-to-net, patient support and market access models.

The conversation examines how evolving payer structures, consumer-driven healthcare decisions and new distribution models are reshaping the patient journey. The group also discusses the growing role of AI and emerging technologies, emphasizing the need to use innovation as an efficiency driver rather than a replacement for human expertise.

Throughout the episode, the panel challenges traditional partnership and launch models, advocating for more collaborative, outcomes-focused approaches built around speed, flexibility and shared accountability. From designing for real-world market conditions to preparing teams to pivot quickly, the discussion offers practical insights for organizations looking to modernize commercialization strategies and improve patient access in a rapidly changing healthcare landscape.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

Like what you’re hearing? Find the full Conversations on Commercialization podcast stream here. Also available anywhere you listen to podcasts.

Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].